Abdelmonem Siddiq

Mr. Abdelmonem Siddiq

Mansoura University, Al Manşūrah, Ad Daqahlīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BOBrando Ortiz-Saavedra
Brando Ortiz-Saavedra
DFDarwin Anthony León Figueroa
Darwin Anthony León Figueroa
EMElizbet Susan Montes-Madariaga
Elizbet Susan Montes-Madariaga
APAlex Ricardo Martínez Pajuelo
Alex Ricardo Martínez Pajuelo
NANiza Alva
Niza Alva
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
During the COVID-19 pandemic, the increase in reports of human monkeypox virus infection cases spreading in many countries outside Africa is a major cause for concern. Therefore, this study aimed to explore the evidence of antiviral pharmacotherapy available for the treatment of adult patients with monkeypox. A scoping review of the literature was conducted using PubMed, Scopus, Web of Science, Embase, and CENTRAL databases until 12 September 2022. The key search terms used were “monkeypox” and “treatment”. A total of 1927 articles were retrieved using the search strategy. After removing duplicates (n = 1007) and examining by title, abstract, and full text, 11 studies reporting case reports of monkeypox with antiviral treatment were included, detailing the number of monkeypox cases, clinical manifestations, number of participants with antiviral treatment, history of sexually transmitted diseases, method of diagnosis, location of skin lesions, drugs used in antiviral treatment, route of administration, and outcome. A total of 1281 confirmed cases of monkeypox have been reported, of which 65 monkeypox cases had antiviral treatment distributed most frequently in the United States (n = 30), the United Kingdom (n = 6), and Spain (n = 6). Of the total cases, 1269 (99.1%) were male with an age range of 18 to 76 years, and 1226 (95.7%) had a sexual behavior of being men who have sex with men. All confirmed cases of monkeypox were diagnosed by reverse transcriptase polymerase chain reaction (RT-PCR). The most frequent clinical manifestations were skin lesions, fever, lymphadenopathy, headache, fatigue, and myalgia. The most frequent locations of the lesions were perianal, genital, facial, and upper and lower extremities. The most commonly used drugs for antiviral treatment of monkeypox were: tecovirimat, cidofovir, and brincidofovir. All patients had a complete recovery. According to current evidence, the efficacy and safety of antiviral drugs against monkeypox is of low quality and scarce.

16 September 2022 in Global Security: Health, Science and Policy
Verified
Journal Article
Open access
Ranjit SahRanjit Sah
Ranjit Sah
Bijaya Kumar PadhiBijaya Kumar Padhi
Bijaya Kumar Padhi
Abdelmonem SiddiqAbdelmonem Siddiq
Abdelmonem Siddiq
AAAbdelaziz Abdelaal
Abdelaziz Abdelaal
ARAbdulla Reda
Abdulla Reda
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Monkeypox (MPX) was a rare endemic disease in western and central Africa. In 1970, the first detected case of human MPX was reported in the Democratic Republic of Congo, and it was detected outside Africa in 2003. Currently, there are about 31,799 confirmed MPX cases which led the WHO to declare the disease a public health emergency of international concern which is considered the seventh deceleration by the WHO between 2009 and 2022. Herein, we aim to review the history behind the outbreak of the disease, its mode of transmission, and the target of WHO deceleration, while providing recommendations for disease prevention. The disease is prevalent mostly in the United States with a total case number of 10,676 which is considered a high-risk country. Meanwhile, other countries are at moderate risk. The disease can be transmitted directly through contact with different body fluids, infectious lesions, or sexual activity. We conclude that there should be high public awareness to stop the transmission of the disease. In addition, there is a great need to follow the instructions provided by public health institutions since vaccines, till now, are available only for high-risk populations secondary to their shortage.

1 September 2022 in Veterinary Quarterly
Verified
Journal Article
Open access
Ranjit SahRanjit Sah
Ranjit Sah
AMAroop Mohanty
Aroop Mohanty
ARAbdullah Reda
Abdullah Reda
Abdelmonem SiddiqAbdelmonem Siddiq
Abdelmonem Siddiq
Ranjan K. MohapatraRanjan K. Mohapatra
Ranjan K. Mohapatra
Kuldeep DhamaKuldeep Dhama
Kuldeep Dhama
Marburg virus (MARV), a highly pathogenic virus, the cause of a deadly disease Marburg virus disease (MVD), has recently been in news during mid of July 2022 owing to its outbreak in Ghana, an Afri...

13 August 2022 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
Ranjit SahRanjit Sah
Ranjit Sah
AMAroop Mohanty
Aroop Mohanty
Abdelmonem SiddiqAbdelmonem Siddiq
Abdelmonem Siddiq
PSParul Singh
Parul Singh
AAAbdelaziz Abdelaal
Abdelaziz Abdelaal
Kuldeep DhamaKuldeep Dhama
Kuldeep Dhama

5 March 2024 in Journal of Infection and Public Health
Verified
Journal Article
Open access
HBHamed Behniafar
Hamed Behniafar
MSMahdi Sepidarkish
Mahdi Sepidarkish
MTMehrdad Jafari Tadi
Mehrdad Jafari Tadi
SVSoghra Valizadeh
Soghra Valizadeh
MGMostafa Gholamrezaei
Mostafa Gholamrezaei
ARAli Rostami
Ali Rostami
This systematic review and meta-analysis study aimed to evaluate global Trichuris infection prevalence, assessing progress towards the WHO's 2030 target. We searched international databases from 2010-2023, categorizing data by regions and socio-economic variables using a random-effects model. Analyzing 757 articles covering 7154,842 individuals from 78 countries, the study found a pooled global prevalence of (6.64-7.57%), with the highest rates in the Caribbean (21.72%; 8.90-38.18%) and South-East Asia (20.95; 15.71-26.71%) regions. Southern Africa (9.58; 2.11-21.46%), Latin America (9.58; 2.11-21.46%), and Middle Africa Middle Africa (8.94; 6.31-11.98%) also exhibited high prevalence. Eastern Europe had the lowest prevalence at 0.16% (0.09-0.24). Approximately 513 (480-547) million people worldwide were estimated to harbor Trichuris. Moreover ∼1.5% of people tested worldwide (2010-2023) had a moderate to heavy intensity of infection. The study emphasizes the persistent global health threat of Trichuris infection, urging tailored strategies for effective control and prevention on a global scale.

1 May 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
DBD. Katterine Bonilla-Aldana
D. Katterine Bonilla-Aldana
JBJorge Luis Bonilla-Aldana
Jorge Luis Bonilla-Aldana
JUJuan R. Ulloque-Badaracco
Juan R. Ulloque-Badaracco
Ali Al-kassab-CórdovaAli Al-kassab-Córdova
Ali Al-kassab-Córdova
EHEnrique A. Hernandez-Bustamante
Enrique A. Hernandez-Bustamante
JSJosé Antonio Suárez
José Antonio Suárez
: Snakebites still constitute a significant public health problem in developing countries and are considered a neglected tropical condition by the WHO. Snake accidents are associated with substantial morbidity and mortality and may produce secondary complications, such as severe infections. The objective of this systematic review was to determine the prevalence of snakebite infections and characterize the bacteria isolated from these infections. A systematic literature review in five databases was carried out to assess the prevalence of snakebite infection. A meta-analysis was performed using a random-effects model to calculate the pooled prevalence and 95% CIs. Cochran’s Q test and the I2 statistic were used to assess between-study heterogeneity. The pooled prevalence of infection due to snakebite was 27.0% (95% CI: 22.0–32.0%), with high heterogeneity among studies (I2 = 99.7%). The prevalence was higher in Asia (32%) than in the Americas (21%). Snakebite infections required surgical interventions in 68% (95% CI: 37.0–98.0%). The leading group of pathogens identified corresponded to Gram-negative bacteria (63%), particularly Morganella morganii (32%), but also, Gram-positive cocci (40%), especially Enterococcus spp. (23%) and Staphylococcus aureus (15%). However, multiple other pathogens, including anaerobes, were found. A high prevalence of snakebite-associated infection has been described, primarily due to M. morganii, with the corresponding implications for empirical therapy. Rational use of antimicrobials is recommended, and this should guide initial empirical treatment. Moreover, isolation and identification of the possible bacteria present in snakebite wounds is recommended in all cases to confirm or rule out associated infection.